MedTrace Logo

Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota

NCT05285449 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-07-03

No results posted yet for this study

Summary

While many empirical projects have described multiple potential health benefits of CBD, the potential for CBD to provide protection against the development of diabetes via favorable modification of the gut microbiota has received relatively less attention. We hope to learn if CBD can improve glucose tolerance and the gut microbiota, and if these two improvements might be related.

Conditions

Interventions

DIETARY_SUPPLEMENT

Cannabidiol (CBD) powder formulation

30 mg CBD in the form of 300 mg of 10% CBD isolate

DIETARY_SUPPLEMENT

Matching Placebo Cannabidiol (CBD) powder formulation

Matching Placebo

Sponsors & Collaborators

  • Caliper Foods

    collaborator UNKNOWN

  • Christopher Bell

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-09
Primary Completion
2023-03-09
Completion
2024-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05285449 on ClinicalTrials.gov